Finasteride: The First 5α‐Reductase Inhibitor

@article{Sudduth1993FinasterideTF,
  title={Finasteride: The First 5$\alpha$‐Reductase Inhibitor},
  author={S. L. Sudduth and M. Koronkowski},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={1993},
  volume={13}
}
Finasteride is a synthetic 4‐azasteroid that is a specific competitive inhibitor of 5α‐reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone (DHT). It has no binding affinity for androgen receptor sites and itself possesses no androgenic, antiandrogenic, or other steroid hormone‐related properties. It is well absorbed after oral administration, with absolute bioavailability in humans of 63% (range 34–108%). The mean time to maximum concentration is 1–2 hours, and… Expand

Topics from this paper

A new look at the 5alpha-reductase inhibitor finasteride.
The influence of low dose finasteride, a type II 5α-reductase inhibitor, on circulating neuroactive steroids
Finasteride‐induced depression: new insights into possible pathomechanisms
5&agr;-Reductase inhibitors in androgenetic alopecia
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 80 REFERENCES
The clinical development of a 5α-reductase inhibitor, finasteride
  • E. Stoner
  • Biology, Medicine
  • The Journal of Steroid Biochemistry and Molecular Biology
  • 1990
Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.
Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans.
...
1
2
3
4
5
...